Drug Transport in the Placenta

Drug Transporters: Molecular Characterization and Role in Drug Disposition: Second Edition

Volumn 9781118489932, Issue , 2014, Pages 341-353

  Mao, Qingcheng ^a   Ganapathy, Vadivel ^b   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

ATP binding cassette (ABC) transporters; Human placenta; Solute carrier (SLC) transporters; Transplacental drug transport

Indexed keywords

GLYCOPROTEINS;

ATP BINDING CASSETTE TRANSPORTERS; DRUG TRANSPORT; EFFLUX TRANSPORTER; HUMAN PLACENTA; IN-VITRO; IT FOCUS; SOLUTE CARRIER TRANSPORTER; SOLUTE CARRIERS; TRANSPLACENTAL DRUG TRANSPORT; VITRO AND IN VIVO;

BIOCHEMISTRY;

EID: 84927131467     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118705308.ch17     Document Type: Chapter

References (103)

1. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN, Platt R. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191 (2):398-407.
2. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol 2003;188 (4):1039-1045.
3. Keegan J, Parva M, Finnegan M, Gerson A, Belden M. Addiction in pregnancy. J Addict Dis 2010;29 (2):175-191.
4. Enders AC, Blankenship TN. Comparative placental structure. Adv Drug Deliv Rev 1999;38 (1):3-15.
5. van der Aa EM, Peereboom-Stegeman JH, Noordhoek J, Gribnau FW, Russel FG. Mechanisms of drug transfer across the human placenta. Pharm World Sci 1998;20 (4):139-148.
6. Myren M, Mose T, Mathiesen L, Knudsen LE. The human placenta-an alternative for studying foetal exposure. Toxicol In Vitro 2007;21 (7):1332-1340.
7. Ni Z, Mao Q. ATP-binding cassette efflux transporters in human placenta. Curr Pharm Biotechnol 2011;12 (4):674-685.
8. Unadkat JD, Dahlin A, Vijay S. Placental drug transporters. Curr Drug Metab 2004;5 (1):125-131.
9. Ganapathy V, Prasad PD, Ganapathy ME, Leibach FH. Placental transporters relevant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther 2000;294 (2):413-420.
10. Vahakangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol 2009;158 (3):665-678.
11. MacFarland A, Abramovich DR, Ewen SW, Pearson CK. Stagespecific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem J 1994;26 (5):417-423.
12. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006;86 (4):1179-1236.
13. Nakamura Y, Ikeda S, Furukawa T, Sumizawa T, Tani A, Akiyama S, Nagata Y. Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun 1997;235 (3):849-853.
14. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 1998;12 (4):457-463.
15. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999;104 (10):1441-1447.
16. Ke AB, Eyal S, Chung FS, Link JM, Mankoff DA, Muzi M, Unadkat JD. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition. J Nucl Med 2013;54:437-446.
17. Eyal S, Chung FS, Muzi M, Link JM, Mankoff DA, Kaddoumi A, O'Sullivan F, Hebert MF, Unadkat JD. Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate. J Nucl Med 2009;50 (5):798-806.
18. Chung FS, Eyal S, Muzi M, Link JM, Mankoff DA, Kaddoumi A, O'Sullivan F, Hsiao P, Unadkat JD. Positron emission tomography imaging of tissue P-glycoprotein activity during pregnancy in the non-human primate. Br J Pharmacol 2010;159 (2):394-404.
19. Pavek P, Fendrich Z, Staud F, Malakova J, Brozmanova H, Laznicek M, Semecky V, Grundmann M, Palicka V. Influence of P-glycoprotein on the transplacental passage of cyclosporine. J Pharm Sci 2001;90 (10):1583-1592.
20. Mathias AA, Hitti J, Unadkat JD. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 2005;289 (4):R963-R969.
21. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspasedependent apoptosis. Proc Natl Acad Sci U S A 1998;95 (12):7024-7029.
22. Kalabis GM, Petropoulos S, Gibb W, Matthews SG. Multidrug resistance phosphoglycoprotein (ABCB1) expression in the guinea pig placenta: developmental changes and regulation by betamethasone. Can J Physiol Pharmacol 2009;87 (11):973-978.
23. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61 (8):3458-3464.
24. Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ ABCG2). Curr Drug Metab 2010;11 (7):603-617.
25. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92 (20):1651-1656.
26. Zhang Y, Wang H, Unadkat JD, Mao Q. Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse. Drug Metab Dispos 2007;35 (12):2154-2158.
27. Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, Mao Q. The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 2008;73 (3):949-959.
28. Wang H, Wu X, Hudkins K, Mikheev A, Zhang H, Gupta A, Unadkat JD, Mao Q. Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am J Physiol Endocrinol Metab 2006;291 (6):E1295-E1304.
29. Cygalova L, Ceckova M, Pavek P, Staud F. Role of breast cancer resistance protein (Bcrp/Abcg2) in fetal protection during gestation in rat. Toxicol Lett 2008;178 (3):176-180.
30. Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Volker U, Kroemer HK. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 2006;34 (4):524-533.
31. Yeboah D, Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor. Can J Physiol Pharmacol 2006;84 (12):1251-1258.
32. Wang H, Lee EW, Zhou L, Leung PC, Ross DD, Unadkat JD, Mao Q. Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol 2008;73 (3):845-854.
33. Evseenko DA, Paxton JW, Keelan JA. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos 2007;35 (4):595-601.
34. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 2004;64 (4):1247-1251.
35. Imai Y, Ishikawa E, Asada S, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 2005;65 (2):596-604.
36. Wang H, Unadkat JD, Mao Q. Hormonal regulation of BCRP expression in human placental BeWo cells. Pharm Res 2008;25 (2):444-452.
37. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 2006;86 (3):849-899.
38. Nagashige M, Ushigome F, Koyabu N, Hirata K, Kawabuchi M, Hirakawa T, Satoh S, Tsukimori K, Nakano H, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. Basal membrane localization of MRP1 in human placental trophoblast. Placenta 2003;24 (10):951-958.
39. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, Meier PJ, Marin JJ. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 2000;279 (4):R1495-R1503.
40. Vaidya SS, Walsh SW, Gerk PM. Formation and efflux of ATP- binding cassette transporter substrate 2,4-dinitrophenyl-S-glutathione from cultured human term placental villous tissue fragments. Mol Pharm 2009;6 (6):1689-1702.
41. May K, Minarikova V, Linnemann K, Zygmunt M, Kroemer HK, Fusch C, Siegmund W. Role of the multidrug transporter proteins ABCB1 and ABCC2 in the diaplacental transport of talinolol in the term human placenta. Drug Metab Dispos 2008;36 (4):740-744.
42. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos 2005;33 (7):896-904.
43. Meyer zu Schwabedissen HE, Grube M, Heydrich B, Linnemann K, Fusch C, Kroemer HK, Jedlitschky G. Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular differentiation. Am J Pathol 2005;166 (1):39-48.
44. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A 1993;90 (6):2542-2546.
45. Ramamoorthy S, Prasad PD, Kulanthaivel P, Leibach FH, Blakely RD, Ganapathy V. Expression of a cocaine-sensitive norepinephrine transporter in the human placental syncytiotrophoblast. Biochemistry 1993;32 (5):1346-1353.
46. Prasad PD, Hoffmans BJ, Moe AJ, Smith CH, Leibach FH, Ganapathy V. Functional expression of the plasma membrane serotonin transporter but not the vesicular monoamine transporter in human placental trophoblasts and choriocarcinoma cells. Placenta 1996;17 (4):201-207.
47. Ganapathy V. Drugs of abuse and human placenta. Life Sci 2011;88 (21-22):926-930.
48. Bonnin A, Goeden N, Chen K, Wilson ML, King J, Shih JC, Blakely RD, Deneris ES, Levitt P. A transient placental source of serotonin for the fetal forebrain. Nature 2011;472 (7343):347-350.
49. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand 2013;127:94-114.
50. Prasad PD, Leibach FH, Mahesh VB, Ganapathy V. Human placenta as a target organ for cocaine action: interaction of cocaine with the placental serotonin transporter. Placenta 1994;15 (3):267-278.
51. Ramamoorthy JD, Ramamoorthy S, Leibach FH, Ganapathy V. Human placental monoamine transporters as targets for amphetamines. Am J Obstet Gynecol 1995;173 (6):1782-1787.
52. Nair BS, Watson RR. Cocaine and the pregnant woman. J Reprod Med 1991;36 (12):862-867.
53. Rizk B, Atterbury JL, Groome LJ. Reproductive risks of cocaine. Hum Reprod Update 1996;2 (1):43-55.
54. Martel F, Keating E. Uptake of 1-methyl-4-phenylpyridinium (MPP+) by the JAR human placental choriocarcinoma cell line: comparison with 5-hydroxytryptamine. Placenta 2003;24 (4):361-369.
55. Schwartz JW, Novarino G, Piston DW, DeFelice LJ. Substrate binding stoichiometry and kinetics of the norepinephrine transporter. J Biol Chem 2005;280 (19):19177-19184.
56. Sommerauer C, Rebernik P, Reither H, Nanoff C, Pifl C. The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine. Neuropharmacology 2012;62 (4):1708-1716.
57. Kenney SP, Kekuda R, Prasad PD, Leibach FH, Devoe LD, Ganapathy V. Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. Am J Obstet Gynecol 1999;181 (2):491-497.
58. Shearman LP, Meyer JS. Cocaine up-regulates norepinephrine transporter binding in the rat placenta. Eur J Pharmacol 1999;386 (1):1-6.
59. Martel F, Azevedo I. An update on the extraneuronal monoamine transporter (EMT): characteristics, distribution and regulation. Curr Drug Metab 2003;4 (4):313-318.
60. Sata R, Ohtani H, Tsujimoto M, Murakami H, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Nagata H, Tsukimori K, Nakano H, Sawada Y. Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther 2005;315 (2):888-895.
61. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 1998;273 (49):32776-32786.
62. Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP. Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol 2001;21 (13):4188-4196.
63. Ahmadimoghaddam D, Hofman J, Zemankova L, Nachtigal P, Dolezelova E, Cerveny L, Ceckova M, Micuda S, Staud F. Synchronized activity of organic cation transporter 3 (Oct3/ Slc22a3) and multidrug and toxin extrusion 1 (Mate1/Slc47a1) transporter in transplacental passage of MPP+ in rat. Toxicol Sci 2012;128 (2):471-481.
64. Ganapathy V, Ganapathy ME, Nair CN, Mahesh VB, Leibach FH. Evidence for an organic cation-proton antiport system in brush-border membranes isolated from the human term placenta. J Biol Chem 1988;263 (10):4561-4568.
65. Simon BJ, Kulanthaivel P, Burckhardt G, Ramamoorthy S, Leibach FH, Ganapathy V. Characterization of an ATP-driven H+ pump in human placental brush-border membrane vesicles. Biochem J 1992;287(Pt 2):423-430.
66. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 2000;275 (6):4507-4512.
67. Ugele B, St-Pierre MV, Pihusch M, Bahn A, Hantschmann P. Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab 2003;284 (2):E390-E398.
68. Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, Kanai Y, Sophasan S, Endou H. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci 2004;94 (3):297-304.
69. Kekuda R, Wang H, Huang W, Pajor AM, Leibach FH, Devoe LD, Prasad PD, Ganapathy V. Primary structure and functional characteristics of a mammalian sodium-coupled high affinity dicarboxylate transporter. J Biol Chem 1999;274 (6):3422-3429.
70. Tamai I. Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharm Drug Dispos 2013;34:29-44.
71. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta 2000;1466 (1-2):315-327.
72. Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, Jung N, Rubbert A, Schomig E. Discovery of the ergothioneine transporter. Proc Natl Acad Sci U S A 2005;102 (14):5256-5261.
73. Grube M, Meyer zu Schwabedissen HE, Draber K, Prager D, Moritz KU, Linnemann K, Fusch C, Jedlitschky G, Kroemer HK. Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab Dispos 2005;33 (1):31-37.
74. Shekhawat PS, Yang HS, Bennett MJ, Carter AL, Matern D, Tamai I, Ganapathy V. Carnitine content and expression of mitochondrial beta-oxidation enzymes in placentas of wild-type (OCTN2(+/+)) and OCTN2 Null (OCTN2(-/-)) Mice. Pediatr Res 2004;56 (3):323-328.
75. Obaidat A, Roth M, Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 2012;52:135-151.
76. Grube M, Reuther S, Meyer zu Schwabedissen HE, Kock K, Draber K, Ritter CA, Fusch C, Jedlitschky G, Kroemer HK. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metab Dispos 2007;35 (1):30-35.
77. Balkovetz DF, Leibach FH, Mahesh VB, Ganapathy V. A proton gradient is the driving force for uphill transport of lactate in human placental brush-border membrane vesicles. J Biol Chem 1988;263 (27):13823-13830.
78. Settle P, Mynett K, Speake P, Champion E, Doughty IM, Sibley CP, D'Souza SW, Glazier J. Polarized lactate transporter activity and expression in the syncytiotrophoblast of the term human placenta. Placenta 2004;25 (6):496-504.
79. Enerson BE, Drewes LR. Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J Pharm Sci 2003;92 (8):1531-1544.
80. Thwaites DT, Anderson CM. H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol 2007;92 (4):603-619.
81. Prasad PD, Ramamoorthy S, Moe AJ, Smith CH, Leibach FH, Ganapathy V. Selective expression of the high-affinity isoform of the folate receptor (FR-alpha) in the human placental syncytiotrophoblast and choriocarcinoma cells. Biochim Biophys Acta 1994;1223 (1):71-75.
82. Ganapathy V, Leibach FH. Human placenta: a direct target for cocaine action. Placenta 1994;15 (8):785-795.
83. Solanky N, Requena Jimenez A, D'Souza SW, Sibley CP, Glazier JD. Expression of folate transporters in human placenta and implications for homocysteine metabolism. Placenta 2010;31 (2):134-143.
84. Prasad PD, Ramamoorthy S, Leibach FH, Ganapathy V. Molecular cloning of the human placental folate transporter. Biochem Biophys Res Commun 1995;206 (2):681-687.
85. Goldman ID, Chattopadhyay S, Zhao R, Moran R. The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs. Curr Opin Investig Drugs 2010;11 (12):1409-1423.
86. Barros LF, Yudilevich DL, Jarvis SM, Beaumont N, Young JD, Baldwin SA. Immunolocalisation of nucleoside transporters in human placental trophoblast and endothelial cells: evidence for multiple transporter isoforms. Pflugers Arch 1995;429 (3):394-399.
87. Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, Davies A, Kwong FY, Coe I, Cass CE, Young JD, Baldwin SA. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 1997;3 (1):89-93.
88. Griffiths M, Yao SY, Abidi F, Phillips SE, Cass CE, Young JD, Baldwin SA. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J 1997; 328 (Pt 3):739-743.
89. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004;447 (5):735-743.
90. Yamamoto T, Kuniki K, Takekuma Y, Hirano T, Iseki K, Sugawara M. Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur J Pharmacol 2007;557 (1):1-8.
91. Sato K, Sai Y, Nishimura T, Chishu T, Shimpo S, Kose N, Nakashima E. Influx mechanism of 2',3'-dideoxyinosine and uridine at the blood-placenta barrier. Placenta 2009;30 (3):263-269.
92. Lee NY, Sai Y, Nakashima E, Ohtsuki S, Kang YS. 6-Mercaptopurine transport by equilibrative nucleoside transporters in conditionally immortalized rat syncytiotrophoblast cell lines TR-TBTs. J Pharm Sci 2011;100 (9):3773-3782.
93. Errasti-Murugarren E, Diaz P, Godoy V, Riquelme G, Pastor-Anglada M. Expression and distribution of nucleoside transporter proteins in the human syncytiotrophoblast. Mol Pharmacol 2011;80 (5):809-817.
94. Cano-Soldado P, Pastor-Anglada M. Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition. Med Res Rev 2012;32 (2):428-457.
95. Sastry BV. Techniques to study human placental transport. Adv Drug Deliv Rev 1999;38 (1):17-39.
96. Stenqvist AC, Chen T, Hedlund M, Dimova T, Nagaeva O, Kjellberg L, Innala E, Mincheva-Nilsson L. An efficient optimized method for isolation of villous trophoblast cells from human early pregnancy placenta suitable for functional and molecular studies. Am J Reprod Immunol 2008;60 (1):33-42.
97. Kliman HJ, Nestler JE, Sermasi E, Sanger JM, Strauss JF III. Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology 1986;118 (4):1567-1582.
98. Ruzycki SM, Kelley LK, Smith CH. Placental amino acid uptake. IV. Transport microvillous membrane vesicles. Am J Physiol 1978;234 (1):C27-C35.
99. Tuntland T, Odinecs A, Pereira CM, Nosbisch C, Unadkat JD. In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus. Am J Obstet Gynecol 1999;180 (1 Pt 1):198-206.
100. Kraemer J, Klein J, Lubetsky A, Koren G. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol 2006;195 (1):270-274.
101. Pollex EK, Hutson JR. Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents. Expert Opin Drug Metab Toxicol 2011;7 (3):325-339.
102. Prasad B, Lai Y, Lin Y, Unadkat JD. Interindividual variability in the hepatic expression of the human breast cancer resistance protein (BCRP/ABCG2): effect of age, sex, and genotype. J Pharm Sci 2013;102 (3):787-793.
103. Deo AK, Prasad B, Balogh L, Lai Y, Unadkat JD. Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry. Drug Metab Dispos 2012;40 (5):852-855.